hepatocellular carcinoma
Conditions
Interventions
Case series:IMRT+ Apatinib
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. aged 18 to 75 years; 2. ECOG performance status between 0 to 1; 3. histologically or cytologically confirmed hepatocellular carcinoma, or meetting the imaging diagnosis of HCC 4. unresectable disease; 5. adequate hematopoietic function (white cell count =3.0 x 10^9/L, absolute neutrophils count =1.5 x 10^9/L, hemoglobin, =100 g/L, platelets = 100 × 10^9/L), hepatc function (Child-Pugh score 5-6, alanine aminotransferase = 2.5 ×ULN, aspartate aminotransferase = 2.5 ×ULN, alkaline phosphatase = 2.5 ×ULN, bilirubin = 1.5 ×ULN, prothrombin time = 1.5 ×ULN, renal function(serum creatinine = 2mg/ml, blood urea nitrogen = 40mg/dl).
Exclusion criteria
Exclusion criteria: 1. ECOG performance status =2; 2. poor hepatc function (Child-Pugh Class C, or Child-Pugh Class B in company with gastrointestinal hemorrhage; 3. hepatic encephalopathy, refractory ascites; 4. Extrahepatic metastasis; 5. Allergic to Apatinib; 6. systemic chemotherapy within 4 weeks; 7. untrolled medical disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| maximum tolerated dose; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dose limiting toxicity; | — |
Countries
China
Contacts
Public ContactWang Wei-hu
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute
Outcome results
None listed